Format

Send to

Choose Destination
J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.

Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.

Author information

1
Department of In Vivo Pharmacology - Oncology, Merck Research Laboratories, Merck & Co., Inc., West Point, PA (BS).

Abstract

Human hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Currently, surgical resection is the only effective treatment for HCC if the tumor is resectable. Small molecule, biologics and siRNA anti-cancer drugs have been explored for the treatment of HCC. Selective targeting to tumor tissue rather than normal liver in HCC patients is still a challenge. Galactosamine-mediated targeting delivery of anti-cancer drugs in the liver has been tested because its receptor, asialoglycoprotein receptor 1 (ASGPR1), is expressed in the liver and not in other human tissues. We examined ASGPR1 expression levels by immunohistochemistry in HCC with different grades. Guidance for a targeting delivery strategy for anti-cancer drugs to HCC is suggested in this report.

KEYWORDS:

ASGPR; galactosamine; galactose; human hepatocellular carcinoma (HCC); immunohistochemistry; targeting delivery

PMID:
23979840
PMCID:
PMC3840742
DOI:
10.1369/0022155413503662
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center